de Latour, R. P., Szer, J., Weitz, I. C., Röth, A., Höchsmann, B., Panse, J., Usuki, K., Griffin, M., Kiladjian, J., de Castro, C. M., Nishimori, H., Ajayi, T., Al-Adhami, M., Deschatelets, P., Francois, C., Grossi, F., Risitano, A. M., & Hillmen, P. (2022). pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial. Lancet, 9(9), e648–e659. http://access.bl.uk/ark:/81055/vdc_100164416497.0x00000a